SNMMI president weighs in on Lymphoseek approval

03/17/2013 | DOTMed.com

SNMMI President Frederic H. Fahey said Lymphoseek, recently approved by the FDA to map the spread of cancer, will improve diagnoses. The drug "lets you be more confident that you are taking the correct lymph node out," Fahey said. The agent employs a targeted approach to seek out the sentinel lymph node, and it can stay in place longer, which can be more convenient for patients, Fahey said.

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI